Author

Li Li

Brown Foundation Institute of Molecular Medicine for the Prevention of Human DiseasesORCID 0000-0002-1313-3916Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Li Li18 papers · Shanghai Jiao Tong University

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

Adela M. Aldana· 2 shared Sheng PaniD· 2 shared Bin Tang YangiD· 1 shared Cara Guernsey-BiddleiD· 1 shared Jake Jianjun WeniD· 1 shared Jianghua TuiD· 1 shared Jie Cui· 1 shared Jin WangiD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Adela M. Aldana

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintOct 18, 2026

Antibody-drug conjugate combination therapy targeting LGR5 and MET with different payloads enhances efficacy in preclinical colorectal cancer models

Shraddha Subramanian, Peyton C. High, Cara Guernsey-Biddle…·Kendra S. Carmon

This study shows that combining LGR5 and MET-targeting antibody-drug conjugates with different payloads improves efficacy and delays tumor relapse in colorectal cancer models.

DOI 10.64898/2026.07.18.739355

humanexperimental assay

𝕏 PostBluesky

Pharmacology & ToxicologyJournal of Medicinal ChemistryPeer-reviewedApr 9, 2026

RSPO2-based peptibodies conjugated with pyrrolobenzodiazepine dimer or camptothecin analogs demonstrate potent anti-tumor activity by targeting the three receptors LGR4/5/6 in colorectal cancer and neuroblastoma

Yukimatsu Toh, Jianghua Tu, Ling Wu…·Qingyun J. Liu

The paper develops RSPO2-based peptibody-drug conjugates that target LGR4/5/6 receptors, showing potent anti-tumor activity in colorectal cancer and neuroblastoma models.

1 citation

humanmouse

𝕏 PostBluesky